The KIT Exon 11 Stop Codon Mutation in Gastrointestinal Stromal Tumors: What Is the Clinical Meaning?
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Gastrointestinal stromal tumors (GISTs) strongly express a receptor tyrosine kinase (RTK, c-KIT-CD117) harboring a KIT mutation that causes constitutive receptor activation leading to the development and growth of tumors; 35% of GISTs without KIT mutations have platelet-derived growth factor receptor alpha (PDGFRA) mutations, and the type of mutation plays an important role in the response to treatment. This study aimed to establish the frequency of stop codon mutations in the RTKs, KIT, and PDGFRA, in GISTs and correlate this molecular alteration with protein expression and treatment responsiveness. Methods: Seventy-nine GISTs were analyzed for both KIT and PDGFRA mutations. Immunohistochemical expression was studied in tissue microarray blocks. Results: We found three rare KIT mutations in exon 11 that induced a stop codon, two at position 563 and one at position 589, which have never been described before. All three tumors were CD117-, DOG1-, and CD34-positive. Two patients with a KIT stop codon mutation did not respond to imatinib therapy and died shortly after treatment. Conclusions: The association between stop codon mutations in KIT and patient survival, if confirmed in a larger population, may be useful in choosing effective therapies.
Abstract
Background/Aims: Gastrointestinal stromal tumors (GISTs) strongly express a receptor tyrosine kinase (RTK, c-KIT-CD117) harboring a KIT mutation that causes constitutive receptor activation leading to the development and growth of tumors; 35% of GISTs without KIT mutations have platelet-derived growth factor receptor alpha (PDGFRA) mutations, and the type of mutation plays an important role in the response to treatment. This study aimed to establish the frequency of stop codon mutations in the RTKs, KIT, and PDGFRA, in GISTs and correlate this molecular alteration with protein expression and treatment responsiveness. Methods: Seventy-nine GISTs were analyzed for both KIT and PDGFRA mutations. Immunohistochemical expression was studied in tissue microarray blocks. Results: We found three rare KIT mutations in exon 11 that induced a stop codon, two at position 563 and one at position 589, which have never been described before. All three tumors were CD117-, DOG1-, and CD34-positive. Two patients with a KIT stop codon mutation did not respond to imatinib therapy and died shortly after treatment. Conclusions: The association between stop codon mutations in KIT and patient survival, if confirmed in a larger population, may be useful in choosing effective therapies.
참고문헌 (24)
- Agaimy A, "Gastrointestinal stromal tumors (GIST) from risk stratification systems to the new TNM proposal: more questions than answers? A review emphasizing the need for a standardized GIST reporting", Int J Clin Exp Pathol, 3, pp.461~471 (2010)
- Hirota S, "Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors", Science, 279, pp.577~580 (1998)
- Miettinen M, "Gastrointestinal stromal tumors: definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis", Virchows Arch, 438, pp.1~12 (2001)
- Liegl B, "Monoclonal antibody DOG1.1 shows higher sensitivity than KIT in the diagnosis of gastrointestinal stromal tumors, including unusual subtypes", Am J Surg Pat, 33, pp.437~446 (2009)
- Longley BJ, "Classes of c-KIT activating mutations: proposed mechanisms of action and implications for disease classification and therapy", Leuk Res, 25, pp.571~576 (2001)
- Rubin BP, "KIT activation is a ubiquitous feature of gastrointestinal stromal tumors", Cancer Res, 61, pp.8118~8121 (2001)
- Kontogianni-Katsarou K, "KIT exon 11 codon 557", 558 deletion, World J Gastroenterol, pp.2008, 14[DOI]
- Heinrich MC, "Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group", J Clin Oncol, 26, pp.5360~5367 (2008)
- Heinrich MC, "Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor", J Clin Oncol, 26, pp.5352~5359 (2008)
- Andersson J, "Gastrointestinal stromal tumors with KIT exon 11 deletions are associated with poor prognosis", Gastroenterology, 130, pp.1573~1581 (2006)
- Nishida T, "Familial gastrointestinal stromal tumours with germline mutation of the KIT gene", Nat Genet, 19, pp.323~324 (1998)
- Allander SV, "Gastrointestinal stromal tumors with KIT mutations exhibit a remarkably homogeneous gene expression profile", Cancer Res, 61, pp.8624~8628 (2001)
- Heinrich MC, "PDGFRA activating mutations in gastrointestinal stromal tumors", Science, 299, pp.708~710 (2003)
- Jones AV, "Oncogenic derivatives of platelet-derived growth factor receptors", Cell Mol Life Sci, 61, pp.2912~2923 (2004)
- Lasota J, "GISTs with PDGFRA exon 14 mutations represent subset of clinically favorable gastric tumors with epithelioid morphology", Lab Invest, 86, pp.94~100 (2006)
- Heinrich MC, "Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor", J Clin Oncol, 21, pp.4342~4349 (2003)
- Stroobants S, "18FDG-Positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec)", Eur J Cancer, 39, pp.2012~2020 (2003)
- Debiec-Rychter M, "Gastrointestinal stromal tumours (GISTs) negative for KIT (CD117 antigen) immunoreactivity", J Pathol, 202, pp.430~438 (2004)
- Vu HA, "A recurrent duodenal gastrointestinal stromal tumor with a frameshift mutation resulting in a stop codon in KIT exon 13", Genes Chromosomes Cancer, 42, pp.179~183 (2005)
- "c-kit Expression and mutations in peripheral T cell lymphomas, except for extra-nodal NK", T cell lymphomas, 2006, pp.47, 267~270[DOI]
- Fletcher CD, "Diagnosis of gastrointestinal stromal tumors: a consensus approach", Hum Pathol, 33, pp.459~465 (2002)
- Kindblom LG, "Gastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal", Am J Pathol, 152, pp.1259~1269 (1998)
- Judson IR, "Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype", J Clin Oncol, 26, pp.5322~5325 (2008)
- Steigen SE, "Mutations in gastrointestinal stromal tumors: a population-based study from Northern Norway", APMIS, 115, pp.289~298 (2007)